Novo Nordisk A/S (NYSE:NVO) presented new analyses from its phase 3 OASIS 4 clinical trial at the European Congress on Obesity 2026 in Istanbul, highlighting the long-term weight loss potential and functional benefits of its oral obesity treatment, Wegovy pill.

The company said adults treated with oral semaglutide 25 mg achieved clinically meaningful weight loss regardless of whether they experienced rapid early reductions in body weight.

Early Responders Saw Greater Long-Term Weight Loss

According to the new analysis, nearly 29% of participants classified as "early responders", those who lost at least 10% of body weight by week 16, recorded average weight loss of 13.2% at that stage of treatment.

By week 64, those early responders achieved an average weight loss of 21.6%.

Participants who did not meet the early-response benchmark still reported average weight loss of 11.5% by the end of the study.